Atossa Genetics (ATOS) to Release Quarterly Earnings on Monday

Key Points

• Atossa Genetics is set to release its Q2 earnings report on August 11th, with analysts expecting a loss of ($0.06) per share for the quarter.
• The company’s stock price recently increased slightly to $0.84 and has a market capitalization of $107.99 million.
• Analysts have recently upgraded Atossa Genetics to a “strong-buy” rating, with price objectives reaching as high as $7.50.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Atossa Genetics to post earnings of ($0.06) per share for the quarter.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Genetics Trading Up 1.9%

ATOS traded up $0.01 during trading hours on Friday, hitting $0.79. The company's stock had a trading volume of 537,868 shares, compared to its average volume of 1,364,935. The business's 50-day moving average price is $0.85 and its 200-day moving average price is $0.80. Atossa Genetics has a 12 month low of $0.55 and a 12 month high of $1.66. The stock has a market cap of $101.66 million, a price-to-earnings ratio of -3.75 and a beta of 0.92.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Atossa Genetics stock. Bank of America Corp DE raised its position in shares of Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) by 51.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 111,475 shares of the company's stock after acquiring an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Genetics worth $105,000 as of its most recent filing with the Securities & Exchange Commission. 12.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ATOS shares. Ascendiant Capital Markets boosted their price target on shares of Atossa Genetics from $7.25 to $7.50 and gave the stock a "buy" rating in a research report on Friday, June 6th. Craig Hallum upgraded shares of Atossa Genetics to a "strong-buy" rating and set a $4.00 price target on the stock in a research report on Thursday, June 5th.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.